|
KMID : 1143220190620040285
|
|
Obstetrics & Gynecology Science
2019 Volume.62 No. 4 p.285 ~ p.289
|
|
|
Long-term survival after intraperitoneal chemotherapy with paclitaxel-cisplatin for recurrent primary peritoneal cancer resistant to multiple lines of intravenous chemotherapy
|
|
Hue Hye-Jeong
Kim Ki-Dong
Kim Hyo-Jin
Suh Dong-Hoon
No Jae-Hong
Kim Yong-Beom
|
|
|
Abstract
|
|
|
|
The long-term survival of heavily pretreated patients with primary peritoneal cancer (PPC) is uncommon. Here, we report on a patient with PPC refractory to multiple lines of intravenous chemotherapy, namely, a combined regimen of paclitaxel and carboplatin, and single regimens of topotecan, docetaxel, cisplatin, and gemcitabine. However, after intraperitoneal (IP) chemotherapy with paclitaxel-cisplatin, the patient's condition improved, and she has been progression-free for more than 4 years. Interestingly, before the IP chemotherapy, the recurrences were limited to the peritoneal cavity. These results suggest that IP recurrence might be a predictor of a good response to IP chemotherapy.
|
|
|
KEYWORD
|
|
|
Peritoneal neoplasms, Neoplasm recurrence, local, Infusions, parenteral, Drug therapy, Ovarian neoplasms
|
|
|
FullTexts / Linksout information
|
|
|
|
|
Listed journal information
|
|
  
|
|